Detalhe da pesquisa
1.
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med
; 16(1): 142, 2018 05 29.
Artigo
Inglês
| MEDLINE | ID: mdl-29843811
2.
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med
; 16(1): 179, 2018 06 29.
Artigo
Inglês
| MEDLINE | ID: mdl-29958537
3.
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Neurooncol Adv
; 6(1): vdae009, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38327681
4.
Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure.
Front Oncol
; 13: 1132777, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37091181
5.
Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure.
Front Oncol
; 13: 1192726, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37093946
6.
A phase I trial of enzastaurin in patients with recurrent gliomas.
Clin Cancer Res
; 15(10): 3617-23, 2009 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19417015
7.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J Clin Oncol
; 27(5): 740-5, 2009 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-19114704
8.
In-111 DTPA ommaya cisternography with delayed radiotracer activity demonstrated in the peritoneal cavity.
Clin Nucl Med
; 34(12): 955-7, 2009 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-20139849